State of New Jersey Common Pension Fund D Trims Holdings in IDEAYA Biosciences, Inc. $IDYA

State of New Jersey Common Pension Fund D lowered its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 68.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,923 shares of the company’s stock after selling 59,438 shares during the period. State of New Jersey Common Pension Fund D’s holdings in IDEAYA Biosciences were worth $931,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Iron Triangle Partners LP acquired a new stake in IDEAYA Biosciences during the 3rd quarter valued at approximately $7,347,000. General American Investors Co. Inc. increased its stake in shares of IDEAYA Biosciences by 7.7% in the third quarter. General American Investors Co. Inc. now owns 280,261 shares of the company’s stock worth $7,626,000 after acquiring an additional 20,000 shares during the period. Candriam S.C.A. raised its holdings in shares of IDEAYA Biosciences by 10.8% during the third quarter. Candriam S.C.A. now owns 1,012,967 shares of the company’s stock worth $27,563,000 after purchasing an additional 98,567 shares during the last quarter. Cinctive Capital Management LP raised its holdings in shares of IDEAYA Biosciences by 193.9% during the third quarter. Cinctive Capital Management LP now owns 49,946 shares of the company’s stock worth $1,359,000 after purchasing an additional 32,953 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in IDEAYA Biosciences by 174.0% during the third quarter. Envestnet Asset Management Inc. now owns 299,032 shares of the company’s stock valued at $8,137,000 after purchasing an additional 189,877 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

IDYA opened at $28.13 on Tuesday. IDEAYA Biosciences, Inc. has a fifty-two week low of $16.84 and a fifty-two week high of $39.28. The company has a fifty day moving average of $31.85 and a two-hundred day moving average of $32.94. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of -17.58 and a beta of -0.04.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The firm had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. During the same quarter in the prior year, the firm posted ($0.82) earnings per share. The firm’s quarterly revenue was down 39.4% on a year-over-year basis. On average, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -4.28 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Guggenheim increased their price target on IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Royal Bank Of Canada boosted their price objective on IDEAYA Biosciences from $49.00 to $53.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Tuesday, April 21st. Wall Street Zen raised IDEAYA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Mizuho reduced their price target on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Fifteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $50.69.

Insiders Place Their Bets

In other IDEAYA Biosciences news, Director Jeffrey Stein purchased 50,000 shares of IDEAYA Biosciences stock in a transaction that occurred on Monday, March 2nd. The stock was bought at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the acquisition, the director owned 54,281 shares of the company’s stock, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.